US Patent

US11103507 — Methods of treating disorders using CSF1R inhibitors

Method of Use · Assigned to Deciphera Pharmaceuticals LLC · Expires 2040-02-03 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating cancers and other tumors, including tenosynovial giant cell tumor, using CSF1R inhibitors.

USPTO Abstract

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Drugs covered by this patent

Romvimza (VIMSELTINIB) · Deciphera Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4145`	—	Romvimza
`U-4145`	—	Romvimza
`U-4145`	—	Romvimza

Patent Metadata

Patent number: US11103507
Jurisdiction: US
Classification: Method of Use
Expires: 2040-02-03
Drug substance claim: No
Drug product claim: No
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.